MiNK Therapeutics (INKT) Competitors $16.26 -0.29 (-1.72%) As of 01:41 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock INKT vs. AARD, BNTC, ESPR, HRTX, SCPH, IVA, ANNX, MREO, MNPR, and LFCRShould you be buying MiNK Therapeutics stock or one of its competitors? The main competitors of MiNK Therapeutics include Aardvark Therapeutics (AARD), Benitec Biopharma (BNTC), Esperion Therapeutics (ESPR), Heron Therapeutics (HRTX), scPharmaceuticals (SCPH), Inventiva (IVA), Annexon (ANNX), Mereo BioPharma Group (MREO), Monopar Therapeutics (MNPR), and Lifecore Biomedical (LFCR). These companies are all part of the "pharmaceutical products" industry. MiNK Therapeutics vs. Its Competitors Aardvark Therapeutics Benitec Biopharma Esperion Therapeutics Heron Therapeutics scPharmaceuticals Inventiva Annexon Mereo BioPharma Group Monopar Therapeutics Lifecore Biomedical MiNK Therapeutics (NASDAQ:INKT) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability. Do insiders & institutionals believe in INKT or AARD? 2.9% of MiNK Therapeutics shares are held by institutional investors. 22.5% of MiNK Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts rate INKT or AARD? MiNK Therapeutics presently has a consensus target price of $37.50, indicating a potential upside of 130.34%. Aardvark Therapeutics has a consensus target price of $33.00, indicating a potential upside of 162.74%. Given Aardvark Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aardvark Therapeutics is more favorable than MiNK Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MiNK Therapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.75Aardvark Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is INKT or AARD more profitable? Company Net Margins Return on Equity Return on Assets MiNK TherapeuticsN/A N/A -140.72% Aardvark Therapeutics N/A N/A N/A Does the media favor INKT or AARD? In the previous week, MiNK Therapeutics and MiNK Therapeutics both had 4 articles in the media. Aardvark Therapeutics' average media sentiment score of 1.15 beat MiNK Therapeutics' score of 1.14 indicating that Aardvark Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiNK Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aardvark Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation and earnings, INKT or AARD? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMiNK TherapeuticsN/AN/A-$9.51M-$2.52-6.46Aardvark TherapeuticsN/AN/A-$20.59MN/AN/A SummaryAardvark Therapeutics beats MiNK Therapeutics on 5 of the 9 factors compared between the two stocks. Get MiNK Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INKT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INKT vs. The Competition Export to ExcelMetricMiNK TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$65.56M$3.04B$5.59B$9.59BDividend YieldN/A2.39%4.71%4.03%P/E Ratio-6.5223.9130.1220.53Price / SalesN/A323.08448.5398.76Price / CashN/A42.5936.0158.40Price / Book-3.308.538.415.79Net Income-$9.51M-$55.06M$3.25B$259.21M7 Day Performance-14.32%-1.47%-1.73%-2.29%1 Month Performance121.80%16.00%8.41%9.09%1 Year Performance73.19%4.16%36.52%15.39% MiNK Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INKTMiNK Therapeutics2.9737 of 5 stars$16.26-1.7%$37.50+130.7%+79.0%$64.84MN/A-6.4530Positive NewsGap DownAARDAardvark TherapeuticsN/A$14.08+4.5%$33.00+134.4%N/A$305.54MN/A0.0018Positive NewsBNTCBenitec Biopharma1.8378 of 5 stars$11.53-3.2%$26.00+125.6%+26.5%$302.53MN/A-7.6320Positive NewsESPREsperion Therapeutics3.9157 of 5 stars$1.50+0.3%$7.00+368.2%-39.2%$296.31M$259.57M-1.87200News CoverageUpcoming EarningsAnalyst RevisionGap DownHRTXHeron Therapeutics3.6006 of 5 stars$1.91+0.3%$5.00+162.5%-36.3%$290.63M$144.29M-31.75300News CoverageUpcoming EarningsSCPHscPharmaceuticals4.3383 of 5 stars$5.40-7.6%$14.00+159.5%+8.7%$284.81M$41.98M-2.8230Positive NewsIVAInventiva3.3079 of 5 stars$2.93-13.7%$10.40+255.6%+31.1%$279.81M$9.95M0.00100News CoveragePositive NewsGap DownHigh Trading VolumeANNXAnnexon2.4733 of 5 stars$2.55-0.2%$12.50+391.2%-58.3%$279.21MN/A-2.1660MREOMereo BioPharma Group1.8172 of 5 stars$1.76+0.9%$7.20+310.3%-56.4%$279.05M$10M-25.0740MNPRMonopar Therapeutics2.4117 of 5 stars$45.06-3.8%$60.00+33.2%+1,118.5%$275.77MN/A-12.9510Positive NewsLFCRLifecore Biomedical1.4519 of 5 stars$7.43+1.1%$8.00+7.7%+12.5%$275.13M$128.26M-5.12690 Related Companies and Tools Related Companies Aardvark Therapeutics Competitors Benitec Biopharma Competitors Esperion Therapeutics Competitors Heron Therapeutics Competitors scPharmaceuticals Competitors Inventiva Competitors Annexon Competitors Mereo BioPharma Group Competitors Monopar Therapeutics Competitors Lifecore Biomedical Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INKT) was last updated on 7/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiNK Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MiNK Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
